448 Shares in iShares Biotechnology ETF (NASDAQ:IBB) Bought by Eastern Bank

Eastern Bank purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 448 shares of the financial services provider’s stock, valued at approximately $65,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC acquired a new position in iShares Biotechnology ETF during the 1st quarter worth $27,000. Bbjs Financial Advisors LLC acquired a new position in iShares Biotechnology ETF during the 2nd quarter worth $31,000. Chris Bulman Inc acquired a new position in iShares Biotechnology ETF during the 2nd quarter worth $64,000. BNP Paribas acquired a new position in shares of iShares Biotechnology ETF in the 1st quarter valued at about $69,000. Finally, Financial Perspectives Inc boosted its holdings in shares of iShares Biotechnology ETF by 23.3% in the 1st quarter. Financial Perspectives Inc now owns 519 shares of the financial services provider’s stock valued at $71,000 after buying an additional 98 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.1 %

NASDAQ IBB opened at $141.51 on Friday. iShares Biotechnology ETF has a one year low of $111.83 and a one year high of $150.57. The company has a 50-day simple moving average of $145.56 and a 200-day simple moving average of $139.99.

iShares Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were issued a $0.2005 dividend. The ex-dividend date was Wednesday, September 25th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.